Vasoconstrictor warning "not appropriate" for single ingredient products -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
VASOCONSTRICTOR WARNING "NOT APPROPRIATE" FOR MONOGRAPH OTCs, NDMA maintains in May 26 comments on FDA's Feb. 23 proposed label warning on vasoconstrictors regarding the possibility of pupil dilation. The Nonprescription Drug Manufacturers Association opposes the warning on single ingredient monograph products, arguing the agency proposal is based on adverse drug experiences (ADEs) for three Rx-to-OTC switch products that contain both a vasoconstrictor and pheniramine maleate, an antihistamine. "The market experience with single ingredient ophthalmic vasoconstrictor products does not demonstrate the same pattern of adverse experience reports and does not warrant FDA's current action," NDMA says.